ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Metformin

Also written as “metformin”, “Metformin XR” and “Fenofibrate /Metformin”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus · Obesity · Fasting · Polycystic Ovary Syndrome, led by 48 companies.

Drug pageMetformin: every studyMany companies study it; this page follows only the 215 they lead. All 1,290 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 9, 2005215 company-led studies, 7 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only290 open or runningphase 3since Nov 9, 2005Nov 9, 2005none ahead
Merckits history only190 open or runningphase 4since Oct 9, 2009Feb 15, 2005none ahead
Sanofiits history only160 open or runningphase 4since Jul 28, 2006Sep 30, 2002none ahead
GlaxoSmithKlineits history only140 open or runningphase 4since Oct 17, 2005Sep 3, 2003none ahead
Takedaits history only120 open or runningphase 4since Sep 17, 2008Jul 30, 2008none ahead
Merck KGaA, Darmstadt, Germanyits history only90 open or runningphase 4since Dec 30, 2011Dec 30, 2011none ahead
Teva Pharmaceutical Industriesits history only90 open or runningphase 1since Jan 30, 2009Jan 30, 2009none ahead
Viatris80 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead
ADIUMits history only70 open or runningno phasesince Jun 3, 2026Jun 3, 2026none ahead
LG Chemits history only70 open or runningphase 3since Feb 6, 2013Aug 22, 2011none ahead

Also a collaborator on its studies: Parexel, PT Pharma Metric Labs, Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene, Eli Lilly and Merck, S.L., Spain.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Viatris only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 30, 2008First studies: 8 phase 1 studies in HealthyFirst studyNCT00650312, NCT00650234, NCT00649948 and 5 more

TargetBeta

“Mitochondrial complex I (NADH dehydrogenase) inhibitor; Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor”ChEMBL 37, by rule

Studies

All 8 Viatris leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00650312Healthy · United States1CompletedOct 200250
NCT00650234Healthy · United States1CompletedMar 200447
NCT00649948Healthy · United States1CompletedMay 200427
NCT00649454Healthy · United States1CompletedJun 200536
NCT00649350Healthy · United States1CompletedDec 200328
NCT00648518Healthy · United States1CompletedDec 200336
NCT00648505Healthy · United States1CompletedJun 200536
NCT00648492Healthy · United States1CompletedNov 200218

How it is read

Names in the registry

  • “Metformin”, 95 entries
  • “metformin”, 33 entries
  • “Metformin XR”, 11 entries
  • “Fenofibrate /Metformin”, 6 entries
  • “Sitagliptin/Metformin FDC”, 5 entries

Codes read as this program: EFB0027.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.